Get the Stockscreener App
0.3367
0.69%
0.0023
Heron Therapeutics Inc stock is traded at $0.3367, with a volume of 1.76M.
It is up +0.69% in the last 24 hours and down -21.68% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$0.3344
Open:
$0.3401
24h Volume:
1.76M
Relative Volume:
0.52
Market Cap:
$63.92M
Revenue:
$150.71M
Net Income/Loss:
$-30.94M
P/E Ratio:
-1.9055
EPS:
-0.1767
Net Cash Flow:
$-20.86M
1W Performance:
-31.40%
1M Performance:
-21.68%
6M Performance:
-70.72%
1Y Performance:
-75.06%
1-Day Range:
$0.3282
$0.3476
1-Week Range:
$0.303
$0.4226
52-Week Range:
$0.303
$1.575
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
0.3367 | 64.72M | 150.71M | -30.94M | -20.86M | -0.1767 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-26 | Downgrade | Needham | Buy → Hold |
| Jun-09-25 | Initiated | H.C. Wainwright | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
HC Wainwright Has Pessimistic Outlook of HRTX Q3 Earnings - MarketBeat
H.C. Wainwright Downgrades Heron Therapeutics(HRTX.US) to Hold Rating - Moomoo
Heron Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com Canada
Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ... - finance.yahoo.com
Heron Therapeutics Q2 2026 Loss Widens 50.0% Beyond Estimates - AlphaStreet
Heron Therapeutics: Q2 Earnings Snapshot - AOL.com
Heron Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Heron Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook - Yahoo Finance
Earnings call transcript: Heron Therapeutics misses Q2 2026 revenue forecast By Investing.com - Investing.com Canada
Heron Therapeutics Q2 Earnings Call Highlights - MarketBeat
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
development in the article - Minichart
Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results - MarketBeat
HERON THERAPEUTICS INC HERON TH (0J4V.L) Q2 FY2026 earnings call transcript - Yahoo Finance
Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook - TradingView
Heron Therapeutics Q2 Revenue Rises To $37.7 Million - Quiver Quantitative
Heron Therapeutics reports Q2 2026 revenue $37.7M, withdraws 2026 guidance after patent ruling - TradingView
Heron Therapeutics Announces Second Quarter 2026 Financial Results - marketscreener.com
Heron Therapeutics (HRTX) Earnings Date and Reports 2026 $HRTX - MarketBeat
Wall Street Zen Upgrades Heron Therapeutics (NASDAQ:HRTX) to Sell - MarketBeat
HERON THERAPEUTICS Q2 2026 Earnings Preview: Recent $HRTX Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Heron Therapeutics Inc expected to post earnings of 1 cent a shareEarnings Preview - TradingView
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Upgraded to Hold at Zacks Research - MarketBeat
Earnings Preview: HRTX to Report Financial Results Pre-market on August 10 - Moomoo
HRTX Q2'26 Earnings: revenue estimate is 42.19M USD - TradingView
Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Monday - MarketBeat
Heron Therapeutics, Inc. Revenue Breakdown – NASDAQ:HRTX - TradingView
Heron Therapeutics Inc (HRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Heron Therapeutics Inc Revenue Breakdown – BX:AXD2 - TradingView
Heron Therapeutics Inc (HRTX) Institutional Confidence - TradingKey
Heron Therapeutics to Report Second Quarter 2026 Financial Results on August 10 - Quiver Quantitative
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026 - The Manila Times
Orbimed Advisors LLC Makes New Investment in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron Therapeutics Inc (HRTX) Cash Flow - TradingKey
Heron Therapeutics Inc (AXD2) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? - Stocktwits
Heron Therapeutics Inc (AXD2) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Heron Therapeutics Inc (HRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Heron Therapeutics Inc (HRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
HRTX|Heron Therapeutics Inc|Price:0.456|Chg%:-0.003 - TradingKey
Heron Therapeutics Inc (HRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - tradingkey.com
VOO Stock Price TodayVanguard S&P 500 ETF News, Charts, Retail Sentiment - Stocktwits
Heron Therapeutics Inc (AXD2) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Heron Therapeutics Inc (AXD2) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Heron Therapeutics Inc (AXD2) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Heron Therapeutics Inc (HRTX) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
HRTX Stock Price, Quote & Chart - ChartMill
Heron Therapeutics Inc (HRTX) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):